Immune system
A cancer-fighting peptide that works like a smart missile—it hunts down and destroys cancer cells by poking holes in them, while leaving your healthy cells completely untouched.
Start here
PNC-27 is an experimental anti-cancer peptide designed to kill cancer cells while leaving healthy cells untouched. It recognizes a protein called HDM-2 that cancer cells display on their outer surface, latches on, and punches holes in the cell's membrane so the cell dies — often within about 4 hours in lab studies. All of the evidence comes from lab and animal research; it is a research compound, not an approved treatment.
Think of PNC-27 as a smart missile designed to destroy only cancer cells. It has two parts: a 'finder' part that recognizes a protein called HDM-2 (which cancer cells foolishly display on their outer surface, while healthy cells keep it locked inside), and a 'destroyer' part that punches holes in the cell membrane. When PNC-27 finds a cancer cell showing HDM-2 on its surface, it latches on and creates tiny pores—like poking holes in a water balloon. The cancer cell's insides leak out and it dies. Healthy cells don't have HDM-2 on their surface, so PNC-27 floats right past them without causing any harm.
PNC-27 is a 32-amino-acid hybrid peptide with two parts. The first part is residues 12-26 of p53 (a protein that tells damaged cells to self-destruct). This piece binds to a pocket on HDM-2/MDM2 (a protein that normally keeps p53 in check). The second part is a membrane residency peptide (MRP), taken from the Antennapedia homeodomain (a protein piece that sticks into cell membranes), which helps PNC-27 anchor in the cell membrane. The peptide takes advantage of an unusual feature of cancer cells. They show HDM-2 in their outer membrane, instead of keeping it inside the cell as normal cells do. When PNC-27 binds to HDM-2 in the membrane, PNC-27 molecules clump into ring-shaped structures about 1-2 micrometers wide. These rings form pores (holes) through the membrane, in a process called 'poptosis.' The holes let the cell's contents leak out quickly, and the cell dies by necrosis (death by bursting), typically within 4 hours. PNC-27 can also get inside cancer cells and damage their mitochondria (the cell's power plants), which gives it a second way to kill. In preclinical (animal or lab studies, not human trials) models (lab and animal studies), the targeting is described as absolute. Cells with HDM-2 in the membrane die rapidly by necrosis, while cells with HDM-2 only inside (normal cells) are left completely unharmed. This differs from apoptosis (the cell's orderly self-destruction) and bypasses many of the ways cancer cells become resistant to standard chemotherapy.
Evidence check
Animal studies only — extensive
It has been studied a lot, but in animals, not people. Results in mice or rats often don't carry over to humans.
Every numbered marker on this page links to one of the 5 sources at the bottom.
Cancer Cell Selectivity
Exclusively targets cancer cells displaying HDM-2 on their surface while completely ignoring healthy cells—demonstrated in every preclinical study
Rapid Action
Kills cancer cells within 4 hours through direct membrane pore formation, faster than most conventional cancer treatments
Broad Spectrum
Effective against multiple cancer types including breast, pancreatic, colon, ovarian, and various leukemias in laboratory studies
The most-asked question
The research-reported range is 1–2 mg, once daily.
The ceiling: 2 mg once daily (based on equivalent animal study dosing)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for PNC-27:
If you have a 5mg vial and add 2.5mL of BAC water, you get a concentration of 2mg/mL. So every 0.1mL (10 units on an insulin syringe) equals 0.2mg of PNC-27.
For a 1mg dose at 2mg/mL concentration: draw 0.5mL (50 units on a standard insulin syringe). Always double-check your math before injecting!
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with PNC-27's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (just under the skin)—it's the easiest method for self-administration
Timing
Morning injections work well for most people—it keeps your schedule consistent and lets you monitor how you feel throughout the day.
You can take PNC-27 with or without food. It doesn't seem to matter for absorption, so do whatever fits your routine.
If you're using other peptides too, inject them at different sites and wait about 30-60 minutes between each one. This helps you track which peptide causes what effect.
The honest list
These show up most often. They usually fade as your body adjusts.
Redness around the injection site is a normal inflammatory response to PNC-27 and to the needle itself. It typically appears within 1-2 hours and fades within 24-48 hours — a sign the immune system is responding, not that tissue is damaged.
What to do Rotate injection sites between abdomen, thigh, and upper arm to allow adequate healing time between injections to the same area. Apply ice packs for 10-15 minutes if redness causes discomfort. If redness persists beyond 48 hours, spreads beyond the injection site, develops red streaking, or is accompanied by warmth/drainage, contact your healthcare provider immediately as this may indicate infection.
Transient fatigue may occur following PNC-27 injection, particularly during the first 1-2 weeks as the immune system mounts its initial response to the peptide. This typically resolves within 4-6 hours post-injection and reflects physiological adaptation rather than toxicity.
What to do Plan injections for times when you can rest if needed—morning dosing allows observation throughout the day. Maintain optimal hydration and sleep patterns. Avoid strenuous exercise for 2-4 hours post-injection. If fatigue persists beyond 24 hours or intensifies with subsequent doses, notify your healthcare provider as this may indicate dose adjustment is needed.
Local heat and tenderness at the injection site are expected inflammatory responses to PNC-27 administration and represent normal tissue reaction to the peptide. Typically most pronounced in the first 6-12 hours and resolves within 24-48 hours as inflammation subsides.
What to do Apply cool (not cold) compresses for 10-15 minutes several times in the first 24 hours to reduce swelling and discomfort. Avoid rubbing or massaging the injection site. Wear loose clothing over the area if pressure bothers you. If warmth lasts beyond 48 hours, spreads more than 2 inches from the injection point, or comes with redness, pus, or fever, contact your healthcare provider immediately — this may be a skin infection (cellulitis).
Worth knowing about, but most people never see these.
Some people get a headache as an early immune response to PNC-27, usually starting within 2-6 hours of injection and clearing within 12-24 hours. It likely comes from inflammation-signaling proteins released as the immune system activates.
What to do Maintain excellent hydration before and after injection. Use NSAIDs like ibuprofen (200-400mg) or acetaminophen (500-1000mg) for symptomatic relief if needed, but check with your protocol supervisor for any contraindications. Apply cool compress to temples or forehead. If headache is severe, persists beyond 24 hours, or is accompanied by neurological symptoms (vision changes, confusion, neck stiffness), contact your healthcare provider.
Mild fever (99-101°F) may accompany PNC-27 administration as a sign of the immune system recognizing and responding to the peptide. This is generally a positive indicator of immune activation rather than infection, and typically resolves within 24-48 hours.
What to do Monitor your core body temperature regularly. Maintain excellent hydration as fever increases fluid loss. Rest and avoid strenuous activity. Use acetaminophen (500-1000mg every 4-6 hours) or ibuprofen (200-400mg every 4-6 hours) if fever causes discomfort. Contact your healthcare provider if fever rises above 101.5°F, lasts longer than 24-48 hours, is accompanied by chills/body aches, or if you develop other concerning symptoms, as this may indicate infection or adverse reaction.
Rare, but if any of these happen, stop and contact a medical professional.
Rare, but possible with any peptide. Signs include hives, major swelling (especially face/throat), difficulty breathing, or feeling like your throat is closing. This is a medical emergency.
What to do STOP using PNC-27 immediately and call 911 or go to an emergency room. If you have an EpiPen for other allergies, use it. This is why having medical supervision is so important.
Week by week
Is it right for you?
PNC-27 is a research compound, not an approved medication. Never start, stop, or change your dosing without guidance from a qualified medical professional or research supervisor. This information is for educational purposes—it's not medical advice.
Could interfere with how PNC-27 works since it relies partly on immune function. Talk to your doctor—you may need to adjust timing or dosing.
May increase bleeding or bruising at injection sites. Not dangerous, but something to watch. Your doctor might want to monitor your clotting levels.
Generally fine for occasional use. They might slightly increase injection site bleeding but nothing serious for most people.
Unknown interactions—PNC-27 works differently than chemo, which could be good or bad. Only combine under oncologist supervision in a research setting.
Generally considered safe to use together. BPC-157 supports healing and gut health, which complements PNC-27's targeted approach. Inject at different sites.
May actually work well together since both support immune function in different ways. Thymosin boosts overall immunity while PNC-27 targets cancer cells specifically.
Safe to combine. GHK-Cu helps with tissue repair and has its own mild anticancer properties. Different mechanisms, so no conflict expected.
Don't use these together. PNC-28 is basically a shorter version of PNC-27 that works the same way. Using both would be redundant and could cause unexpected effects.
Safe and potentially helpful. Vitamin D supports immune function, which could complement PNC-27's effects.
Safe to take together. Zinc is important for immune health and wound healing from injections.
Safe to combine. May have mild blood-thinning effects, so watch for extra bruising at injection sites, but nothing dangerous.
Theoretical concern here: PNC-27 kills cancer cells partly through oxidative stress (cell damage from unstable oxygen molecules). Flooding your body with antioxidants might interfere. Stick to normal supplement doses.
PNC-27 has shown remarkable results against solid tumors in lab studies. It's been tested against breast, pancreatic, colon, and ovarian cancer cells—and in each case, it killed the cancer cells while the healthy cells next to them stayed perfectly fine. That's the holy grail of cancer research.
In studies on acute myeloid leukemia (AML), PNC-27 wiped out cancer cells within just 4 hours. It works on several types of leukemia cells (U937, OCI-AML3, HL-60) by targeting a protein that only shows up on cancer cell surfaces. Normal blood cells? Completely unharmed.
Here's where PNC-27 gets really interesting: it can kill cancer stem cells. These are the sneaky cells that often survive chemo and cause cancer to come back. PNC-27 has shown it can destroy CD44+ colon cancer stem cells (colon cancer stem cells that carry a marker protein called CD44), which is a big deal for preventing recurrence.
When cancers stop responding to regular chemotherapy, researchers need new approaches. PNC-27 works through a completely different mechanism than traditional chemo drugs, so it may be effective against cancers that have become resistant to other treatments.
Here's the really cool thing about PNC-27: in all the lab and animal studies so far, it ONLY attacks cancer cells. Normal, healthy cells are completely ignored because they don't have the protein (HDM-2) on their surface that PNC-27 targets. Animal studies using doses up to 40 mg/kg showed tumors shrinking or disappearing with zero damage to normal tissues. That said, it hasn't been tested in human clinical trials yet, so we're still learning.
The safety data comes from extensive cell studies and animal experiments—not human trials. The science behind why it's selective is solid (cancer cells uniquely express HDM-2 on their surface), but always work with a medical professional when using research compounds.
Keeping it good
Keep your PNC-27 powder in the freezer (-4°F to -112°F / -20°C to -80°C). It should stay in its original sealed vial, away from light. A properly stored vial can last up to 3 years. Don't let it sit at room temperature.
Once you've mixed it with BAC water, move it to the refrigerator (36-46°F / 2-8°C). Never freeze the mixed solution—that destroys the peptide. Keep it away from light and use it within 14 days.
Not our opinion — the published record
2022
This study showed exactly how PNC-27 kills cancer cells: it binds to HDM-2 proteins on cancer cell membranes, forms ring-shaped structures, and pokes holes that cause the cell to burst. Normal cells without surface HDM-2 are completely ignored.
Sarafraz-Yazdi E, Mumin S, Engel D, et al.
2020
PNC-27 killed three different types of leukemia cells (U937, OCI-AML3, HL-60) within just 4 hours, but left normal blood-forming cells completely unharmed. This selectivity is what makes PNC-27 so exciting for cancer research.
Thadi A, Forber M, Engel D, et al.
2021
PNC-27 successfully killed cancer stem cells (CD44+ cells) from colon cancer—this is huge because cancer stem cells often survive regular chemo and cause cancer to come back. Normal colon cells were not affected.
Thadi A, Esposito M, Bhargava S, et al.
2010
Researchers confirmed that PNC-27 stays intact when it kills cancer cells—it doesn't break down into smaller pieces first. The whole peptide binds to cancer cell membranes and creates physical holes, causing the cells to die by necrosis.
Sookraj KA, Bowne WB, Adler V, et al.
2010
This foundational study proved that PNC-27 specifically binds to HDM-2 protein in cancer cell membranes (not inside cells). Since normal cells keep HDM-2 inside the cell, PNC-27 can't target them. It's like cancer cells have a 'target' sign only PNC-27 can see.
Sookraj KA, Bowne WB, Adler V, et al.
If this isn't the right fit
Your questions
It's all about a protein called HDM-2. In healthy cells, HDM-2 stays inside the cell where it belongs. But cancer cells make a mistake—they put HDM-2 on their outer surface like a flag. PNC-27 is designed to recognize and bind to that flag. No flag on the surface? PNC-27 ignores the cell completely. This is why it can kill cancer cells without harming the healthy ones right next to them.
No, not yet. PNC-27 is currently a research compound that has shown very promising results in lab studies and animal experiments. It hasn't gone through human clinical trials yet, which are required for FDA approval. That's why it's only available for research purposes and should only be used under proper medical or scientific supervision.
In lab studies, PNC-27 has successfully killed cells from breast cancer, pancreatic cancer, colon cancer, ovarian cancer, and several types of leukemia (AML, acute monocytic leukemia, acute promyelocytic leukemia). It's also been shown to kill cancer stem cells, which is exciting because these cells often survive regular chemotherapy.
Remarkably fast compared to most cancer treatments. In laboratory studies, PNC-27 killed cancer cells within 4 hours of exposure. It works by physically creating holes in cancer cell membranes, so the effect is pretty immediate once it binds to its target. Of course, shrinking actual tumors in a body takes longer and depends on many factors.
That's not something anyone can recommend right now. PNC-27 hasn't been tested in human clinical trials, so we don't know how it works in actual cancer patients—only in lab dishes and animals. Never replace proven treatments with experimental ones without your oncologist's guidance. PNC-27 might one day be used alongside or instead of chemo, but that's still being researched.
Great science takes time. PNC-27 has been studied since the mid-2000s, and the research is genuinely exciting. But moving from lab success to approved medicine takes years of clinical trials, massive funding, and navigating regulatory hurdles. Many promising compounds are in this 'valley' between lab discovery and clinical use. PNC-27 is working its way through that process.
They're cousins, basically. PNC-27 contains p53 residues 12-26, while PNC-28 is shorter with just residues 17-26. Both target HDM-2 on cancer cell membranes, but PNC-27 is generally more potent because it has a longer binding region. Researchers study both to understand which parts of the sequence are most important for killing cancer cells.
The biggest risk with any peptide is allergic reaction, though it's rare. In animal studies, PNC-27 showed no damage to normal tissues—which is amazing and unusual for cancer treatments. However, it hasn't been tested in humans yet, so there could be risks we don't know about. That's why medical supervision is absolutely essential.
5 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the PNC-27 research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. PNC-27 is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek